Patents by Inventor Miki Aihara

Miki Aihara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240216389
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: March 13, 2024
    Publication date: July 4, 2024
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki Aihara, Shizuo Kinoshita
  • Patent number: 11957691
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: April 16, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • Publication number: 20220241293
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: September 15, 2021
    Publication date: August 4, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki Aihara, Shizuo Kinoshita
  • Patent number: 11147821
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: October 19, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • Patent number: 11013746
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: May 25, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • Publication number: 20190374549
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: January 17, 2019
    Publication date: December 12, 2019
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
  • Publication number: 20190117666
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 25, 2019
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
  • Publication number: 20170239265
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
  • Publication number: 20170196877
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: March 29, 2017
    Publication date: July 13, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
  • Patent number: 9669075
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: June 6, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • Patent number: 9636382
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: May 2, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • Patent number: 9597283
    Abstract: This invention provides an injectable formulation to be administered intramuscularly or subcutaneously that is used for the prevention or treatment of polycystic kidney disease, and that can maintain a therapeutically effective blood concentration of tolvaptan for a long period of time; and a process for producing the same. More specifically, this invention relates to an injectable depot formulation comprising (1) a particle containing optically active tolvaptan as an active ingredient and (2) a pharmaceutically acceptable carrier for injection, and a process for producing the same.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: March 21, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Daiki Kaneko, Takakuni Matsuda, Kenichi Miyata, Kai Suzuki, Hiroyuki Fujiki, Shizuo Kinoshita, Koji Ohmoto, Miki Aihara
  • Publication number: 20160250222
    Abstract: The present invention provides a combined drug for an injectable depot formulation having a superior effect of preventing and/or treating polycystic kidney disease. More specifically, the present invention relates to a drug for preventing and/or treating polycystic kidney disease, which is an injectable depot formulation comprising a particle containing tolvaptan or a prodrug thereof and a somatostatin analogue. The present invention also relates to a method for preventing and/or treating polycystic kidney disease using the drug.
    Type: Application
    Filed: October 14, 2014
    Publication date: September 1, 2016
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki AIHARA, Katsuji HATTORI, Koji OHMOTO, Takakuni MATSUDA, Daiki KANEKO
  • Publication number: 20160058841
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: November 9, 2015
    Publication date: March 3, 2016
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
  • Publication number: 20150352041
    Abstract: This invention provides an injectable formulation to be administered intramuscularly or subcutaneously that is used for the prevention or treatment of polycystic kidney disease, and that can maintain a therapeutically effective blood concentration of tolvaptan for a long period of time; and a process for producing the same. More specifically, this invention relates to an injectable depot formulation comprising (1) a particle containing optically active tolvaptan as an active ingredient and (2) a pharmaceutically acceptable carrier for injection, and a process for producing the same.
    Type: Application
    Filed: December 27, 2013
    Publication date: December 10, 2015
    Inventors: Daiki KANEKO, Takakuni MATSUDA, Kenichi MIYATA, Kai SUZUKI, Hiroyuki FUJIKI, Shizuo KINOSHITA, Koji OHMOTO, Miki AIHARA
  • Publication number: 20150141338
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 21, 2015
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • Patent number: 5637597
    Abstract: The present invention provides agents for inhibiting production of interleukin-8 and for inhibiting granulocytes activation as well as novel method for curing inflamatory diseases. The agents for inhibiting production of interleukin-8, and for inhibiting granulocytes activation and for curing inflammatory diseases, which contains as an active ingredient, a carbostyril derivative represented by the general formula (I): ##STR1## where R is as described in the specification.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 10, 1997
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Takahide Matsuda, Shigeru Owada, Hiroshi Muta, Miki Aihara, Hisao Takizawa, Ken-ichi Imagawa, Mikio Kikuchi